Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: biomachine56 who wrote (2179)	5/28/2013 10:34:37 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2344

Again, thanks for the good stuff. A few trading days, and we'll be through the 866/CRC data and waiting on slides/tweets from Chicago, re. distribution of long-term survivors. Arrived! Best of luck! Rick

To: biomachine56 who wrote (2179)	12/8/2013 9:52:17 PM
From: scaram(o)uche	Respond to of 2344

twitter.com Don't know if that link will work for the entire conversation, I'm not particularly good at twitter. Ms. Church says, agreeing with you, says that 765 (pan PI3K/mTOR) is dead on arrival for lymphomas. However, Serono (collaborating with Sanofi) RECENTLY initiated a phase II with MEK inhibitor pimasertib in ovarian Ca..... clinicaltrials.gov (if one can survive the treatment, the cancer ought damn well be inhibited) Moreover, whether practical or not, it appears that the plug has not been pulled on 147 either....... clinicaltrials.gov